Switch theme
Sign up to access all valuation multiples
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The company is mainly involved in the design, development, manufacture, and sale of energy-based aesthetic medical and minimally invasive treatment systems, non-EBD devices, and cosmeceuticals. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
2013
1.0K+
LTM Revenue $375M
LTM EBITDA $46.6M
$244M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sisram Medical has a last 12-month revenue (LTM) of $375M and a last 12-month EBITDA of $46.6M.
In the most recent fiscal year, Sisram Medical achieved revenue of $44.6M and an EBITDA of $6.7M.
Sisram Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sisram Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $375M | XXX | $44.6M | XXX | XXX | XXX |
| Gross Profit | $237M | XXX | $27.7M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $46.6M | XXX | $6.7M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $25.7M | XXX | $4.6M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $30.1M | XXX | $3.2M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sisram Medical's stock price is HKD 5 (or $1).
Sisram Medical has current market cap of HKD 2.1B (or $273M), and EV of HKD 1.9B (or $244M).
See Sisram Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $244M | $273M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sisram Medical has market cap of $273M and EV of $244M.
Sisram Medical's trades at 5.5x EV/Revenue multiple, and 36.5x EV/EBITDA.
Equity research analysts estimate Sisram Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sisram Medical has a P/E ratio of 9.1x.
See valuation multiples for Sisram Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $273M | XXX | $273M | XXX | XXX | XXX |
| EV (current) | $244M | XXX | $244M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 36.5x | XXX | XXX | XXX |
| EV/EBIT | 9.5x | XXX | 53.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.1x | XXX | 85.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 127.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSisram Medical's last 12 month revenue growth is 19%
Sisram Medical's revenue per employee in the last FY averaged $44K, while opex per employee averaged $23K for the same period.
Sisram Medical's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sisram Medical's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sisram Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 231% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 175% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $23K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sisram Medical acquired XXX companies to date.
Last acquisition by Sisram Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Sisram Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sisram Medical founded? | Sisram Medical was founded in 2013. |
| Where is Sisram Medical headquartered? | Sisram Medical is headquartered in Hong Kong. |
| How many employees does Sisram Medical have? | As of today, Sisram Medical has 1.0K+ employees. |
| Is Sisram Medical publicy listed? | Yes, Sisram Medical is a public company listed on HKG. |
| What is the stock symbol of Sisram Medical? | Sisram Medical trades under 01696 ticker. |
| When did Sisram Medical go public? | Sisram Medical went public in 2017. |
| Who are competitors of Sisram Medical? | Similar companies to Sisram Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sisram Medical? | Sisram Medical's current market cap is $273M |
| What is the current revenue of Sisram Medical? | Sisram Medical's last 12 months revenue is $375M. |
| What is the current revenue growth of Sisram Medical? | Sisram Medical revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Sisram Medical? | Current revenue multiple of Sisram Medical is 0.7x. |
| Is Sisram Medical profitable? | Yes, Sisram Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sisram Medical? | Sisram Medical's last 12 months EBITDA is $46.6M. |
| What is Sisram Medical's EBITDA margin? | Sisram Medical's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Sisram Medical? | Current EBITDA multiple of Sisram Medical is 5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
